Mr. Yifftach Biel reports

DIAGNOSTEAR TECHNOLOGIES INC. ANNOUNCES WARRANT EXTENSION

Diagnostear Technologies Inc. has extended the expiry date of 5,733,885 outstanding common share purchase warrants (the November, 2024, warrants) and 133,333 outstanding common share purchase warrants (the December, 2024, warrants).

The November, 2024, warrants were issued in connection with a non-brokered private placement of subscription receipts and in connection with the RTO (reverse takeover) transaction (as previously announced on a news release on Nov. 21, 2024).

The December, 2024, warrants were issued in connection with a non-brokered private placement of units of common shares.

The initial exercise price of the November, 2024, warrants and the December, 2024, warrants is $1 and remains unchanged.

The November, 2024, warrants had an original expiry date of May 20, 2026. The December, 2024, warrants had an original expiry date of June 2, 2026. The company proposes to extend the expiry date of the November, 2024, warrants and the December, 2024, warrants by an additional six months such that the November, 2024, warrants will expire on Nov. 20, 2026, and the December, 2024, warrants will expire on Dec. 2, 2026. All other terms and conditions of the November, 2024, and the December, 2024, warrants will remain unchanged.

The extension is subject to final approval by the Canadian Securities Exchange; however, the CSE has granted an exemption from the requirement of Section 6.7(c) (no warrants having been exercised in the last six months) of CSE Policy 6 to permit the company to undertake the extension. No action will be required on the part of the holders of the November, 2024, and December, 2024, warrants to give effect to the extension, and replacement warrant certificates will not be issued. Original warrant certificates must be presented to the company in order to exercise any of the November, 2024, and December, 2024, warrants.

About Diagnostear Technologies Inc.

Diagnostear is a leading ophthalmic company developing and commercializing disruptive diagnostic solutions for better management of eye diseases. Diagnostear's TeaRx technology is a diagnostic platform intended for rapid, point-of-care testing (POCT) of ophthalmic pathologies through multiparameter analysis of non-invasively collected tear fluid. The first CE-IVD and Israeli MoH-approved test based on the TeaRx platform is intended for diagnosis of dry eye syndrome (DES TeaRx Dry Eye). This product is not FDA-cleared (U.S. Food and Drug Administration) yet. Beyond DES, Diagnostear is developing innovative tests based on the TeaRx platform for additional ophthalmic indications. Among others, Diagnostear's pipeline includes TeaRx Red Eye: the first test of its kind for differential assessment of adenoviral conjunctivitis, herpetic keratitis and allergic conjunctivitis.

We seek Safe Harbor.